Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Utpal Dave, MD
Primary Investigator
Brief description of study
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Peripheral T-cell Lymphoma (PTCL)
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- 18 years or older
- Histological confirmation of peripheral T-cell lymphoma (PTCL)
For a full list of participation criteria, please visit clinicaltrials.gov.
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
